Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-(4,4-dimethyl-3-(6-(3-(2-oxazolyl)propyl)-3-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl)-3-fluoro-2-(trifluoromethyl)benzonitrile
2. Gt 0918
3. Gt-0918
4. Gt0918
1. 1398046-21-3
2. Pruxelutamide
3. Gt-0918
4. Proxalutamide [who-dd]
5. Qx6o64gp40
6. 4-(4,4-dimethyl-3-(6-(3-(2-oxazolyl)propyl)-3-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl)-3-fluoro-2-(trifluoromethyl)-benzonitrile
7. 4-[4,4-dimethyl-3-[6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile
8. 4-(4,4-dimethyl-3-(6-(3-(oxazol-2-yl)propyl)pyridin-3-yl)-5-oxo-2-thioxoimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzonitrile
9. Unii-qx6o64gp40
10. Pruxelutamide [inn]
11. Chembl4594417
12. Schembl12494226
13. Gtpl11992
14. Dtxsid901102678
15. Ex-a5434
16. Gt0918
17. At29744
18. Sb17303
19. Hy-103184
20. Cs-0025229
21. Q27287540
22. 4-(4,4-dimethyl-3-(6-(3-(oxazol-2-yl)propyl)pyridin-3-yl)-5-oxo-2-thioxoimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl) Benzonitrile
| Molecular Weight | 517.5 g/mol |
|---|---|
| Molecular Formula | C24H19F4N5O2S |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 6 |
| Exact Mass | 517.11955869 g/mol |
| Monoisotopic Mass | 517.11955869 g/mol |
| Topological Polar Surface Area | 118 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 894 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Proxalutamide is an antagonist at the androgen receptor which leads to inhibition of androgen-induced receptor activation and results in formation of inactive complexes that are not able to translocate to the nucleus. It also induces androgen receptor downregulation, furthering adrogen-induced receptor activation. This drug is being investigated for its potential antineoplastic activity and is being investigated specifically against prostate cancer and COVID-19.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Proxalutamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Proxalutamide, including repackagers and relabelers. The FDA regulates Proxalutamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Proxalutamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Proxalutamide supplier is an individual or a company that provides Proxalutamide active pharmaceutical ingredient (API) or Proxalutamide finished formulations upon request. The Proxalutamide suppliers may include Proxalutamide API manufacturers, exporters, distributors and traders.
Proxalutamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Proxalutamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Proxalutamide GMP manufacturer or Proxalutamide GMP API supplier for your needs.
A Proxalutamide CoA (Certificate of Analysis) is a formal document that attests to Proxalutamide's compliance with Proxalutamide specifications and serves as a tool for batch-level quality control.
Proxalutamide CoA mostly includes findings from lab analyses of a specific batch. For each Proxalutamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Proxalutamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Proxalutamide EP), Proxalutamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Proxalutamide USP).
LOOKING FOR A SUPPLIER?
